Allergan Announces Focus On ALPHAGAN P; Plans to Discontinue Alphagan.

Business Editors & Health/Medical Writers

Allergan, Inc. (NYSE:AGN) today announced that due to the overwhelming adoption of the improved brimonidine solution ALPHAGAN(R) P (Brimonidine tartrate ophthalmic solution) 0.15%, preserved with Purite(R), the company intends to focus its manufacturing, sales and marketing efforts on ALPHAGAN(R) P and plans to discontinue U.S. distribution of Alphagan(R) (Brimonidine tartrate ophthalmic solution) 0.2%.

ALPHAGAN(R) P has been shown in two twelve-month clinical studies to be comparable in efficacy to Alphagan(R), but with lower rates of certain adverse events, including a reduction in the incidence of ocular allergy. ALPHAGAN(R) P, which is indicated for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension, is the first glaucoma product to be preserved with Purite(R).

Research demonstrates that a vast majority of ophthalmologists and optometrists surveyed prefer ALPHAGAN(R) P to the original Alphagan(R) brand and do not see a medical need for having both products on the market.

Forward-Looking Statements

Statements regarding future plans, forecasts, and events are "forward-looking statements." These statements are based on current expectations and intentions only. If underlying assumptions prove inaccurate, or unknown risks or uncertainties materialize, actual results could vary materially from the company's expectations. Risks and uncertainties include general industry and pharmaceutical market conditions; general domestic and international economic conditions; technological advances, patents and products attained by competitors; challenges inherent in product marketing such as the unpredictability of market acceptance for a pharmaceutical product; potential difficulties in manufacturing a product formulation; domestic and foreign health care reforms; and trends toward managed care and health care cost containment, and governmental laws and regulations affecting domestic and foreign operations. Additional information concerning these and other risk factors can be found in press releases issued by Allergan as well as Allergan's public periodic filings with the Securities and Exchange Commission, including the discussion under the heading "Certain Factors and Trends Affecting Allergan and Its Businesses" in Allergan's 2001 Annual Report on Form 10-K and Form 10-Q for the quarter ended March 29, 2002. Allergan's filings are available publicly and upon request from Allergan's Investor Relations Department: 714.246.4636 or http://www.allergan.com.

About Allergan, Inc.

Allergan, Inc., with headquarters in Irvine, California, is a technology-driven, global health care company providing eye care and specialty pharmaceutical products worldwide. Allergan develops and commercializes products in the eye care, neuromuscular and skin care markets that deliver value to our customers, satisfy unmet medical needs, and improve patients' lives.